X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Subject to the terms of the agreement, Frontier Biotechnologies will be responsible for all development costs for AFFITOPE® AT04 occurring in Greater China and will receive the rights to develop, manufacture and exclusively commercialize AT04 in the licensed territory.
Lead Product(s): Affitope AT04,Aluminium Oxyhydroxide
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Affitope AT04
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Frontier Biotechnologies
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement December 22, 2021
Details:
AC Immune is acquiring AFFiRiS’ anti-alpha-synuclein programs (PD01) targeting neurodegenerative diseases caused by misfolded forms of human self-proteins. All acquired programs are based on AFFiRiS´ AFFITOME® technology.
Lead Product(s): PD01
Therapeutic Area: Neurology Product Name: PD01
Highest Development Status: Phase IProduct Type: Vaccine
Partner/Sponsor/Collaborator: AC Immune
Deal Size: $100.8 million Upfront Cash: $5.0 million
Deal Type: Acquisition July 27, 2021
Details:
AFFITOPE® peptide vaccine candidates AT04A and AT06A are safe, well-tolerated and induces a strong and long-lasting PCSK9-specific immune response in the cardiovascular disease indication hypercholesterolemia.
Lead Product(s): AT04A
Therapeutic Area: Cardiology/Vascular Diseases Product Name: AT04A
Highest Development Status: Phase IProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 27, 2021
Details:
Human mtHTT transgenic mice treated with mAB C6-17 showed significantly reduced mtHTT levels in peripheral organs and central nervous system and displayed improved motor performance.
Lead Product(s): mAB C6-17
Therapeutic Area: Genetic Disease Product Name: mAB C6-17
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 27, 2021
Details:
In its written response, the FDA addressed AFFiRiS' questions and provided guidance on the design of the planned phase 2 trial.
Lead Product(s): PD01
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Phase IProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 27, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
